If you are looking for a textbook example of how to completely mismanage expectations, look no further than the obesity drug sector and VIVUS, Inc. (NASDAQ:VVUS). After suffering a rejection by the FDA, VVUS clawed its way back and got approval for its prescription obesity drug (now marketed as Qysmia) and in conjunction saw its share price triple in the first 7 months of 2012.
A couple years and countless bagholders later, VVUS finds its stock price at its lowest levels since 2009 and the future isn't any brighter based on its current trajectory. It is for that reason (among others) that the recent developments about a potential buyout should be taken with a huge grain of salt.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|